| 2018 |
| 02/28 | 2,953 | 2,972 | 2,938 | 2,943 | -0.88% | 32,300 | 847億5840万 | +0.31% |
| 02/27 | 2,979 | 2,979 | 2,912 | 2,969 | -0.34% | 26,200 | 855億720万 | +0.88% |
| 02/26 | 2,923 | 2,992 | 2,917 | 2,979 | +1.92% | 39,000 | 857億9520万 | +1.15% |
| 02/23 | 2,922 | 2,935 | 2,868 | 2,923 | +2.38% | 45,200 | 841億8240万 | -0.78% |
| 02/22 | 2,860 | 2,869 | 2,801 | 2,855 | +1.42% | 45,300 | 822億2400万 | -3.25% |
| 02/21 | 2,751 | 2,834 | 2,736 | 2,815 | +2.33% | 48,700 | 810億7200万 | -4.9% |
| 02/20 | 2,752 | 2,784 | 2,744 | 2,751 | +0.55% | 34,200 | 792億2880万 | -7.4% |
| 02/19 | 2,718 | 2,737 | 2,694 | 2,736 | -0.87% | 68,200 | 787億9680万 | -8.37% |
| 02/16 | （IR情報）15:00 アレルゲン免疫療法薬TO-203（ミティキュア ダニ舌下錠）の小児適応に係る用法・用量の追加承認取得について |
| 02/16 | 2,750 | 2,799 | 2,745 | 2,760 | -0.11% | 42,200 | 794億8800万 | -7.97% |
| 02/15 | （IR情報）15:00 譲渡制限付株式報酬制度の導入に関するお知らせ |
| 02/15 | 2,739 | 2,822 | 2,733 | 2,763 | +0.88% | 30,100 | 795億7440万 | -8.24% |
| 02/14 | 2,770 | 2,785 | 2,720 | 2,739 | -1.12% | 28,600 | 788億8320万 | -9.39% |
| 02/13 | 2,800 | 2,859 | 2,762 | 2,770 | +0.51% | 50,700 | 797億7600万 | -8.76% |
| 02/09 | 2,683 | 2,810 | 2,683 | 2,756 | -0.33% | 87,400 | 793億7280万 | -9.64% |
| 02/08 | 2,702 | 2,791 | 2,702 | 2,765 | +3.13% | 82,800 | 796億3200万 | -9.7% |
| 02/07 | 2,905 | 2,925 | 2,680 | 2,681 | -7.65% | 191,600 | 772億1280万 | -12.73% |
| 02/06 | （IR情報）15:00 2017年12月期決算参考資料 |
| 02/06 | （IR情報）15:00 平成29年12月期決算短信〔日本基準〕(非連結) |
| 02/06 | （IR情報）15:00 役員の異動に関するお知らせ |
| 02/06 | 2,990 | 3,010 | 2,820 | 2,903 | -4.82% | 116,900 | 836億640万 | -5.87% |
| 02/05 | 3,035 | 3,070 | 3,035 | 3,050 | -1.77% | 32,500 | 878億4000万 | -1.13% |
| 02/02 | 3,130 | 3,130 | 3,100 | 3,105 | -0.32% | 19,000 | 894億2400万 | +0.75% |
| 02/01 | 3,090 | 3,120 | 3,075 | 3,115 | +0.81% | 24,800 | 897億1200万 | +1.3% |
| 01/31 | 3,095 | 3,130 | 3,080 | 3,090 | -0.8% | 31,000 | 889億9200万 | +0.75% |
| 01/30 | 3,150 | 3,150 | 3,100 | 3,115 | -1.74% | 51,100 | 897億1200万 | +1.76% |
| 01/29 | 3,205 | 3,215 | 3,155 | 3,170 | -1.09% | 33,400 | 912億9600万 | +3.8% |
| 01/26 | 3,200 | 3,220 | 3,190 | 3,205 | 0% | 35,900 | 923億400万 | +5.25% |
| 01/25 | 3,200 | 3,235 | 3,185 | 3,205 | +0.63% | 67,000 | 923億400万 | +5.53% |
| 01/24 | 3,130 | 3,195 | 3,110 | 3,185 | +0.79% | 121,100 | 917億2800万 | +5.12% |
| 01/23 | 3,295 | 3,305 | 3,125 | 3,160 | +4.64% | 391,500 | 910億800万 | +4.46% |
| 01/22 | （IR情報）15:00 平成29年12月期通期業績予想の修正に関するお知らせ |
| 01/22 | 3,005 | 3,020 | 2,996 | 3,020 | +0.33% | 16,100 | 869億7600万 | -0.03% |
| 01/19 | 3,045 | 3,050 | 3,000 | 3,010 | -1.47% | 14,000 | 866億8800万 | -0.4% |
| 01/18 | 3,085 | 3,085 | 3,050 | 3,055 | -0.97% | 22,300 | 879億8400万 | +0.99% |
| 01/17 | 3,090 | 3,090 | 3,065 | 3,085 | -0.16% | 16,200 | 888億4800万 | +1.98% |
| 01/16 | 3,115 | 3,115 | 3,085 | 3,090 | -0.8% | 12,200 | 889億9200万 | +2.18% |
| 01/15 | 3,075 | 3,115 | 3,075 | 3,115 | +1.96% | 31,900 | 897億1200万 | +3.21% |
| 01/12 | （IR情報）15:00 JAK阻害剤（皮膚外用製剤）JTE-052の国内第3相臨床試験（比較試験）の速報結果について |
| 01/12 | 3,050 | 3,070 | 3,040 | 3,055 | -0.33% | 20,200 | 879億8400万 | +1.33% |
| 01/11 | 3,065 | 3,065 | 3,040 | 3,065 | -0.33% | 18,300 | 882億7200万 | +1.73% |
| 01/10 | 3,055 | 3,080 | 3,030 | 3,075 | +0.33% | 20,700 | 885億6000万 | +2.16% |
| 01/09 | 3,100 | 3,105 | 3,055 | 3,065 | -1.45% | 23,800 | 882億7200万 | +1.96% |
| 01/05 | 3,050 | 3,120 | 3,045 | 3,110 | +1.97% | 40,100 | 895億6800万 | +3.56% |
| 01/04 | 3,020 | 3,060 | 3,020 | 3,050 | +0.83% | 28,500 | 878億4000万 | +1.67% |
| 2017 |
| 12/29 | 2,977 | 3,025 | 2,965 | 3,025 | +1.78% | 23,500 | 871億2000万 | +0.93% |
| 12/28 | 2,949 | 2,983 | 2,944 | 2,972 | +0.95% | 26,200 | 855億9360万 | -0.83% |
| 12/27 | 2,926 | 2,945 | 2,911 | 2,944 | -0.41% | 32,600 | 847億8720万 | -1.83% |
| 12/26 | 2,940 | 2,960 | 2,940 | 2,956 | +0.61% | 52,900 | 851億3280万 | -1.6% |
| 12/25 | 2,919 | 2,941 | 2,912 | 2,938 | +0.65% | 20,200 | 846億1440万 | -2.33% |
| 12/22 | 2,931 | 2,931 | 2,901 | 2,919 | -0.41% | 25,300 | 840億6720万 | -3.06% |
| 12/21 | 2,944 | 2,954 | 2,924 | 2,931 | -0.54% | 21,800 | 844億1280万 | -2.85% |
| 12/20 | 2,940 | 2,954 | 2,916 | 2,947 | -0.03% | 36,400 | 848億7360万 | -2.51% |
| 12/19 | 2,988 | 2,988 | 2,948 | 2,948 | -1.54% | 30,900 | 849億240万 | -2.67% |
| 12/18 | 3,030 | 3,030 | 2,987 | 2,994 | -1.19% | 40,700 | 862億2720万 | -1.35% |
| 12/15 | （IR情報）15:00 組織変更及び人事異動のお知らせ |
| 12/15 | 3,050 | 3,065 | 3,015 | 3,030 | -0.82% | 23,700 | 872億6400万 | -0.33% |
| 12/14 | 3,095 | 3,100 | 3,035 | 3,055 | -0.81% | 27,000 | 879億8400万 | +0.39% |
| 12/13 | 3,110 | 3,110 | 3,065 | 3,080 | +1.32% | 42,400 | 887億400万 | +1.18% |
| 12/12 | 3,070 | 3,070 | 3,035 | 3,040 | -0.98% | 13,700 | 875億5200万 | -0.13% |
| 12/11 | 3,070 | 3,120 | 3,035 | 3,070 | +0.49% | 26,900 | 884億1600万 | +0.82% |
| 12/08 | 3,145 | 3,165 | 3,030 | 3,055 | -0.65% | 80,400 | 879億8400万 | +0.33% |
| 12/07 | 2,928 | 3,080 | 2,920 | 3,075 | +4.31% | 53,900 | 885億6000万 | +0.99% |
| 12/06 | 3,000 | 3,015 | 2,945 | 2,948 | -2.55% | 48,600 | 849億240万 | -3.19% |
| 12/05 | 3,005 | 3,035 | 3,000 | 3,025 | +0.5% | 32,500 | 871億2000万 | -0.75% |
| 12/04 | 2,972 | 3,050 | 2,970 | 3,010 | +0.43% | 78,100 | 866億8800万 | -1.34% |
| 12/01 | 2,971 | 3,040 | 2,969 | 2,997 | +1.15% | 41,900 | 863億1360万 | -1.96% |
| 11/30 | 2,985 | 2,987 | 2,951 | 2,963 | -1.23% | 40,600 | 853億3440万 | -3.26% |
| 11/29 | 3,020 | 3,020 | 2,991 | 3,000 | -0.66% | 42,600 | 864億 | -2.44% |
| 11/28 | 3,015 | 3,025 | 2,993 | 3,020 | +0.94% | 36,400 | 869億7600万 | -2.01% |
| 11/27 | （5%ルール）エフィッシモキャピタルマネージメントピーティーイ…（8.43%） |
| 11/27 | 3,000 | 3,010 | 2,988 | 2,992 | -0.6% | 12,100 | 861億6960万 | -3.14% |
| 11/24 | 3,025 | 3,025 | 2,995 | 3,010 | -0.5% | 15,100 | 866億8800万 | -2.78% |
| 11/22 | 3,075 | 3,075 | 3,015 | 3,025 | -1.63% | 16,000 | 871億2000万 | -2.48% |
| 11/21 | 3,070 | 3,090 | 3,045 | 3,075 | +0.65% | 15,900 | 885億6000万 | -1.09% |
| 11/20 | 3,030 | 3,070 | 3,005 | 3,055 | +1.16% | 17,500 | 879億8400万 | -1.93% |
| 11/17 | 3,070 | 3,085 | 3,010 | 3,020 | -1.63% | 39,300 | 869億7600万 | -3.24% |
| 11/16 | 3,065 | 3,105 | 3,065 | 3,070 | -0.16% | 15,100 | 884億1600万 | -1.85% |
| 11/15 | 3,075 | 3,100 | 3,065 | 3,075 | -0.81% | 32,600 | 885億6000万 | -1.79% |
| 11/14 | 3,095 | 3,135 | 3,085 | 3,100 | +0.49% | 21,500 | 892億8000万 | -1.08% |
| 11/13 | 3,095 | 3,100 | 3,040 | 3,085 | -0.96% | 36,800 | 888億4800万 | -1.69% |
| 11/10 | 3,070 | 3,120 | 3,070 | 3,115 | -0.32% | 20,200 | 897億1200万 | -0.89% |
| 11/09 | 3,105 | 3,130 | 3,085 | 3,125 | +1.46% | 44,200 | 900億 | -0.7% |
| 11/08 | 3,035 | 3,085 | 3,035 | 3,080 | +0.49% | 12,900 | 887億400万 | -2.19% |
| 11/07 | 3,070 | 3,070 | 3,035 | 3,065 | -0.16% | 33,800 | 882億7200万 | -2.79% |
| 11/06 | 3,060 | 3,075 | 3,035 | 3,070 | +0.33% | 17,900 | 884億1600万 | -2.79% |
| 11/02 | 3,055 | 3,065 | 3,035 | 3,060 | 0% | 20,700 | 881億2800万 | -3.32% |
| 11/01 | 3,070 | 3,075 | 3,040 | 3,060 | -0.33% | 21,400 | 881億2800万 | -3.29% |
| 10/31 | 3,080 | 3,080 | 3,040 | 3,070 | +0.99% | 30,900 | 884億1600万 | -2.94% |
| 10/30 | 3,095 | 3,115 | 3,025 | 3,040 | -1.78% | 60,100 | 875億5200万 | -3.83% |
| 10/27 | 3,020 | 3,115 | 3,020 | 3,095 | -2.06% | 74,200 | 891億3600万 | -2.03% |
| 10/26 | （IR情報）15:00 2017年12月期第3四半期決算参考資料 |
| 10/26 | （IR情報）15:00 平成29年12月期第3四半期決算短信〔日本基準〕(非連結) |
| 10/26 | 3,140 | 3,180 | 3,115 | 3,160 | +0.16% | 35,000 | 910億800万 | +0.19% |
| 10/25 | 3,220 | 3,225 | 3,150 | 3,155 | -2.92% | 40,300 | 908億6400万 | +0.22% |
| 10/24 | 3,200 | 3,250 | 3,190 | 3,250 | +1.88% | 43,000 | 936億 | +3.47% |
| 10/23 | 3,180 | 3,195 | 3,165 | 3,190 | +0.31% | 20,600 | 918億7200万 | +1.98% |
| 10/20 | 3,150 | 3,195 | 3,150 | 3,180 | +0.63% | 19,900 | 915億8400万 | +1.99% |
| 10/19 | 3,145 | 3,180 | 3,145 | 3,160 | -0.16% | 21,300 | 910億800万 | +1.71% |
| 10/18 | 3,225 | 3,225 | 3,150 | 3,165 | -1.56% | 42,000 | 911億5200万 | +2.2% |
| 10/17 | 3,205 | 3,225 | 3,170 | 3,215 | +0.16% | 35,200 | 925億9200万 | +4.18% |
| 10/16 | 3,190 | 3,240 | 3,190 | 3,210 | +0.16% | 29,700 | 924億4800万 | +4.53% |
| 10/13 | 3,165 | 3,215 | 3,165 | 3,205 | +0.47% | 31,900 | 923億400万 | +4.88% |
| 10/12 | 3,170 | 3,205 | 3,165 | 3,190 | +1.11% | 21,400 | 918億7200万 | +4.9% |
| 10/11 | 3,170 | 3,170 | 3,150 | 3,155 | -0.16% | 18,100 | 908億6400万 | +4.26% |
| 10/10 | 3,180 | 3,180 | 3,150 | 3,160 | -0.63% | 19,300 | 910億800万 | +4.84% |
| 10/06 | 3,215 | 3,230 | 3,165 | 3,180 | -1.24% | 76,000 | 915億8400万 | +5.79% |
| 10/05 | （IR情報）15:00 スギ花粉症に対するアレルゲン免疫療法薬「シダキュアスギ花粉舌下錠」の発売予定時期に関するお知らせ |
| 10/05 | 3,195 | 3,225 | 3,190 | 3,220 | +0.16% | 25,400 | 927億3600万 | +7.44% |
| 10/04 | 3,170 | 3,235 | 3,155 | 3,215 | +0.94% | 37,200 | 925億9200万 | +7.63% |
| 10/03 | 3,180 | 3,200 | 3,130 | 3,185 | +0.47% | 39,300 | 917億2800万 | +7.09% |
| 10/02 | 3,170 | 3,190 | 3,160 | 3,170 | -0.94% | 35,100 | 912億9600万 | +6.99% |
| 09/27 | （IR情報）16:00 スギ花粉症に対するアレルゲン免疫療法薬「シダキュアスギ花粉舌下錠」の国内製造販売承認取得について |
